Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2024-07-12 00:00:00 ET · period of report 2024-07-10 · accession 0000950170-24-083200 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-12 | 2024-07-10 | ANTX | Eizen Joshua M | CLO | A - Grant | $0.00 | +60.0K | 94.8K | +172% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-10 | A | A | 60,000 | $0.00 | 94,833 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs"). RSUs vest as follows: 25% vest on January 1, 2025, 50% vest on January 1, 2026 and 25% vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date. (F3) Reflects the adjusted total which includes the purchase of 2,386 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2024. (F2) Includes a balance of 30,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. |